ATXS
Price
$5.77
Change
+$0.17 (+3.04%)
Updated
Jun 13, 02:31 PM (EDT)
Capitalization
316.03M
59 days until earnings call
URGN
Price
$11.08
Change
+$3.78 (+51.78%)
Updated
Jun 12 closing price
Capitalization
510.87M
67 days until earnings call
Interact to see
Advertisement

ATXS vs URGN

Header iconATXS vs URGN Comparison
Open Charts ATXS vs URGNBanner chart's image
Astria Therapeutics
Price$5.77
Change+$0.17 (+3.04%)
Volume$650
Capitalization316.03M
UroGen Pharma
Price$11.08
Change+$3.78 (+51.78%)
Volume$21.08M
Capitalization510.87M
ATXS vs URGN Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. URGN commentary
Jun 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and URGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (ATXS: $5.60 vs. URGN: $11.08)
Brand notoriety: ATXS and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 55% vs. URGN: 812%
Market capitalization -- ATXS: $316.03M vs. URGN: $510.87M
ATXS [@Biotechnology] is valued at $316.03M. URGN’s [@Biotechnology] market capitalization is $510.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $352B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • URGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than URGN.

Price Growth

ATXS (@Biotechnology) experienced а +7.28% price change this week, while URGN (@Biotechnology) price change was +115.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.78%. For the same industry, the average monthly price growth was +21.12%, and the average quarterly price growth was +7.56%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+8.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($511M) has a higher market cap than ATXS($316M). URGN YTD gains are higher at: 4.038 vs. ATXS (-37.360). URGN (-119.79M) and ATXS (-124.4M) have comparable annual earnings (EBITDA) . ATXS has more cash in the bank: 295M vs. URGN (196M). ATXS has less debt than URGN: ATXS (5.06M) vs URGN (125M). URGN has higher revenues than ATXS: URGN (91.9M) vs ATXS (0).
ATXSURGNATXS / URGN
Capitalization316M511M62%
EBITDA-124.4M-119.79M104%
Gain YTD-37.3604.038-925%
P/E RatioN/AN/A-
Revenue091.9M-
Total Cash295M196M151%
Total Debt5.06M125M4%
FUNDAMENTALS RATINGS
ATXS vs URGN: Fundamental Ratings
ATXS
URGN
OUTLOOK RATING
1..100
2420
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5794
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is in the same range as URGN (73). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as URGN (100). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as URGN (100). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

ATXS's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for URGN (94). This means that ATXS’s stock grew somewhat faster than URGN’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as URGN (100). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSURGN
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWGGX11.800.09
+0.77%
American Century Focused Global Gr Inv
MSFFX19.370.06
+0.31%
MFS Total Return R1
KSMIX9.09N/A
N/A
Keeley Small-Mid Cap Value I
AATSX18.92-0.01
-0.05%
Ancora/Thelen Small-Mid Cap S
ACFGX74.78-0.14
-0.19%
American Century Focused Dynamic Gr G

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-3.28%
DNLI - ATXS
58%
Loosely correlated
-1.74%
CRNX - ATXS
54%
Loosely correlated
-0.49%
XENE - ATXS
54%
Loosely correlated
+1.67%
TRDA - ATXS
53%
Loosely correlated
-0.63%
COGT - ATXS
52%
Loosely correlated
-0.55%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with RVMD. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+51.78%
RVMD - URGN
43%
Loosely correlated
+0.78%
MREO - URGN
40%
Loosely correlated
+4.91%
IMNM - URGN
39%
Loosely correlated
+3.16%
ATXS - URGN
39%
Loosely correlated
-3.28%
BEAM - URGN
39%
Loosely correlated
-2.52%
More